
Gland Pharma Limited has informed the Exchange regarding a press release dated July 23, 2024, titled "Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution ".
Filed with NSE ·

Gland Pharma Limited has informed the Exchange regarding a press release dated July 23, 2024, titled "Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution ".
6ix hasn’t read this filing yet.
Follow Gland Pharma into a list and get an email when it puts out news.
Follow Gland Pharma